Takeda Other Liab from 2010 to 2024

TAK Stock  USD 13.49  0.11  0.82%   
Takeda Pharmaceutical Other Liabilities yearly trend continues to be quite stable with very little volatility. Other Liabilities may rise above about 713.1 B this year. From the period between 2010 and 2024, Takeda Pharmaceutical, Other Liabilities regression line of its data series had standard deviation of  437,468,337,657 and standard deviation of  437,468,337,657. View All Fundamentals
 
Other Liabilities  
First Reported
2017-12-31
Previous Quarter
544.1 B
Current Value
454 B
Quarterly Volatility
483.9 B
 
Covid
Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 764.4 B, Interest Expense of 125.5 B or Selling General Administrative of 783 B, as well as many indicators such as Price To Sales Ratio of 1.45, Dividend Yield of 0.0463 or PTB Ratio of 0.85. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Latest Takeda Pharmaceutical's Other Liab Growth Pattern

Below is the plot of the Other Liab of Takeda Pharmaceutical Co over the last few years. It is Takeda Pharmaceutical's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Takeda Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

Takeda Other Liab Regression Statistics

Arithmetic Mean479,171,028,357
Geometric Mean114,085,033,635
Coefficient Of Variation91.30
Mean Deviation368,064,644,301
Median374,921,000,000
Standard Deviation437,468,337,657
Sample Variance191378546452.3T
Range1.2T
R-Value0.76
Mean Square Error86429387300.9T
R-Squared0.58
Significance0.001
Slope74,539,481,758
Total Sum of Squares2679299650331.6T

Takeda Other Liab History

2024713.1 B
2023625.7 B
2022544.1 B
20211.2 T
2020831 B
20191.1 T
20181.1 T

About Takeda Pharmaceutical Financial Statements

Takeda Pharmaceutical investors utilize fundamental indicators, such as Other Liab, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities625.7 B713.1 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.049
Dividend Share
192
Earnings Share
0.59
Revenue Per Share
1.4 K
Quarterly Revenue Growth
0.127
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.